BodeVet – Elephant Disease Causes Death by Hemorrhage… Lyophilized Platelets May Help

February 1, 2018 -- Cellphire, Inc., the global leader in long-term stabilization and storage of platelets and other cells, announced today that the in-human care population of elephants is plagued by an endotheliotropic herpes virus that attacks young elephants and causes an acute loss of platelets with associated bleeding. 

BodeVet, Inc. working with the Smithsonian Institute has begun the process of producing lyophilized platelets for zoos to have available when bleeding occurs. A clinical trial is proposed to determine if platelet transfusion improves outcome saving these magnificent animals from death. 

# # #

About Cellphire, Inc.

Cellphire, Inc., based in Rockville, Maryland, is the only U.S. company developing freeze-dried platelet products. Cellphire is focused on applying its cellular stabilization technology to all cell types in order to provide lifesaving products where none are routinely available. Platelets are critical to the body’s vascular system and responsible for the body’s ability to stop bleeding. Unlike other blood products that can be frozen and stockpiled for use when needed, platelet products currently used can only be stored for 5-7 days. Cellphire’s lead product, Thrombosomes®, a human platelet derived hemostatic agent, uses a proprietary technology to freeze-dry platelets into a product that can be stored for years, then reconstituted with sterilized water. Cellphire’s platform technology has potential applications across a wide range of cell types and medical applications from trauma to wound care, imaging, targeted drug delivery and regenerative medicine.  This project has been funded in whole or in part with federal funds from the Biomedical Advanced Research and Development Authority (BARDA), Office of the Assistant Secretary for Preparedness and Response, Office of the Secretary, Department of Health and Human Services, under Contract No. HHSO100201300021C.  For more information, please view

About BodeVet, Inc.

BodeVet, Inc. is a wholly owned subsidiary of Cellphire, Inc. formed in 2016. BodeVet uses technology licensed from Cellphire to develop and market veterinary therapeutics.  Cellphire’s lead product, Thrombosomes®, is a stable, platelet-derived hemostatic agent that was tested for safety and efficacy in canine and rabbit models, and based on that data FDA’s Center for Veterinary Medicine (CVM) allowed the company to commercialize its freeze-dried platelet-derived products for animals. BodeVet’s first commercial product, StablePlate RX®, is a canine freeze-dried platelet product that was launched at IVECCS in September 2017. Although primarily focused on canine and equine conditions, BodeVet is also supporting work on endangered species (elephants, cheetah and rhinos).  BodeVet is staffed and advised by world leaders in veterinary medicine, and its team works closely with Cellphire to ensure that Cellphire’s technologies are translated as effectively as possible to veterinary applications in order to save and improve animals’ lives. For more information, please view

Cautionary Note Regarding Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “anticipated”, “believe”, “expect”, “may”, “plan”, “potential”, “will”, and similar expressions, and are based on Cellphire’s current beliefs and expectations. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials, increased regulatory requirements, Cellphire’s reliance on third parties over which it may not always have full control, and others. Any forward-looking statements speak only as of the date of this press release and are based on information available to Cellphire as of the date of this release, and Cellphire assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.



Thomas Dann
(240) 268-2489

Source:  Cellphire, Inc.